3 reasons Celgene Corporation (NASDAQ:CELG) stock owners should not worry about Revlimid

- May 15, 2017

Revlimid is Celgene Corporation’s (NASDAQ:CELG) cancer drug that did about $7 billion in sales last year. Celgene Corporation (NASDAQ:CELG) has patent exclusivity on Revlimid for another half-decade, but still, when a drug has such significant sales, and is so crucial to a company’s future, it is only natural that CELG stock owners show concern.

Celgene stock owners wonder how much more Revlimid has in the tank. When will it peak? Celgene Corporation (NASDAQ:CELG) management claims that Revlimid’s best days are still ahead, but that’s hard to believe given how Revlimid has already exceeded all expectations.

Still, there are three big reasons why CELG stock owners should worry less about Revlimid, and realize the deep value in Celgene stock at just 13.5x forward earnings.

First, Revlimid sales are actually accelerating! As seen in the chart below, sales for the drug have accelerated in each of the last three years. That’s quite a feat. Furthermore, it suggests that sales of the drug won’t fall from a cliff anytime soon.

Second, Celgene Corporation (NASDAQ:CELG) is relying less and less on Revlimid.

This is perhaps the most surprising chart of all to a casual investor with basic knowledge of Celgene Corporation (NASDAQ:CELG). Despite Revlimid’s accelerated growth over the last year especially, it is actually responsible for less of the company’s total revenue than ever before.

Currently, Revlimid accounts for 60.66% of Celgene Corporation (NASDAQ:CELG) total revenue. That’s down from 64.5% two years ago, and 70% in 2010.

Yes, Revlimid is still very important for the future of Celgene Corporation (NASDAQ:CELG)  and CELG stock. However, it is clear that Celgene Corporation (NASDAQ:CELG) has more than just one piece to its puzzle.

Third, Otezla is a major catalyst in the making.

Last year, Celgene’s psoriatic arthritis drug Otezla topped $1 billion in global sales with growth of more than 100% compared to 2015.

Management said that sales could top $1.5 billion this year. In the first quarter, sales of Otezla grew just 24% to $242 million. However, international markets were a huge driver with $43 million and an increase of 105% year-over-year. Looking ahead, Otezla could easily top $2 billion in annual sales as Celgene Corporation (NASDAQ:CELG) launches the drug in various European markets, Japan, Asia, and Latin America.

Beyond Otezla, Pomalyst/Imnovid remains a growth driver, as is the inevitable launch of mega-blockbuster MS drug Ozanimod. 

Needless to say, there’s a lot to be excited about, if you are a Celgene stock owner.

This entry was posted in HADE Platform, Healthcare & Biotech, Members Bookmark the permalink.
RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Join the 100s Who Beat the Market with a BNL Membership

See What Current Members Are Saying

My Complete Access BNL Membership Includes

  • No contract. Guaranteed results. Cancel anytime.
  • Unrivaled Performance. The BNL Portfolio has outperformed the S&P 500 by 150% since October 1, 2015
  • Access. You know what goes in the BNL Portfolio, David’s Dividend Portfolio, and Eddy’s Options.
  • Alerts. You know when a trade is made in all three managed portfolios with application, text, and email alerts
  • Transparency. Verifiable trade records for the BNL Portfolio, David’s Dividends, & Eddy’s Options
  • Research. We have coverage on more than 50 companies
  • Results. Our 10 highest rated stocks outperformed the market by 134% last year
  • Live Chat. Join 100s of other members in an exclusive Members Only section with Chat
  • Growth. We are the fastest growing financial research platform in our industry.
  • Build My Portfolio. You give us your goals, we help you get there
  • Premium Content. Unlock hidden sections in each article. You also get Value of the Month selections and BNL Research Reports.
  • Community. We have professionals and beginners; retirees and college students; the 99% & 1%, but here, we are all equal.

Like what you see? Sign up for our newsletter and get the latest stock picks straight to your email!